Low Dose Naltrexone Therapy

Time 2020-11-23 16:05:22

Web Name: Low Dose Naltrexone Therapy

WebSite: http://ldners.org

ID:125025

Keywords:

Dose,Low,Therapy,

Description:

This is the long anticipated collaboration of leading scientific researchers investigating LDN therapies. A MedInsight Research Institute project. organizers of International LDN Awareness Week have launched LDNAware, gateway to worldwide LDN groups, information and activism. The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders Published by McFarland Publishing Available at Amazon / Barnes Noble Book Description Order Sheet Commentaries:RonaldHoffman, MD | JeffreyDach. MD | YashAgrawal, MD, PhD Book Review by Maija Haavisto The off-label protocol referred to as Low Dose Naltrexone (LDN) modulates the immune system and promotes healing. Relying on clinical trial results and interviews with the leading LDN researchers worldwide, we describe the history of LDN and explain its biochemical and molecular effects. In clinical trials, LDN has been shown to halt disease progression in Crohn’s disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis (MS) and autism. Ongoing trials are evaluating LDN in fibromyalgia and HIV/AIDS. Anecdotally, LDN has been shown to improve almost every autoimmune and neurodegenerative condition, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Elaine Moore for making this book a reality. She is extensively published medical author. This book will be an invaluable reference for researchers, practitioners and patients who want to understand the therapeutic potential of LDN. experienced remarkable recovery from MS misery. Research is proving that using a low dose of the FDA approved drug Naltrexone is helpful in treating many immune system disorders. LDNers.org is dedicated to helping patients get better with LDN. Join SammyJo on Facebook Sign the World LDN Petition Over 11,400 so far! Post Your LDN Results Patient Tracking Database Meet the LDN Advocates! Vicki Finlayson walked 53 miles for LDN research! Radio interviews with Elaine Moore SammyJo Wilkinson, authors of the The Promise Of Low Dose Naltrexone Therapy. Follow these links to listen live on the Web or to the show archive. Interview: Burt Berkson, MD, PhD, Talks With Honest Medicine About His Work With Alpha Lipoic Acid and Low Dose Naltrexone (audio text) New! LDN Patient Tracking Database for all diseases. Post your results! MS survey matches SammyJo's 2004 survey for comparison. This is no longer just anecdotes - this is Patient Based Evidence! Read Julia Schopick's Anecdotal Series: Six Articles A Case of Remission from Crohn's Disease. Reported Jeffrey Dach MD LDN commentary by Yash Agrawal, MD Dec 20, Dr. Agrawal adds some further thoughts to the his hypothesis on LDN for MS, published in 2005. And comments on the new LDN book, for which he wrote the foreward. Low-dose naltrexone for disease prevention and quality of life Nov 26, Brown N, Panksepp J., Medical Hypotheses. Overview of current trials and theories on how LDN benefits a wide variety of illnesses. Abstract. Four LDN Studies Presented at the 2008 MS World Congress Meeting Sept 22nd, Elaine Moore reports on the important MS/LDN studies at Penn State and University of California. Low Dose Naltrexone: Hope for PPMS Sept 18th, Maija Haavisto reports on the Italian human trial 6 month report. This is the first LDN-MS trial data published - Abstract J. Mult. Scler. Sept 08 Daily Mail reports another positive LDN story Aug 25th The Daily Mail, London Wonder Drug: LDN has potential to help tens-of-thousands of patients with diseases like Crohn's, multiple sclerosis, Lupus, parkinson's and even HIV. (News interviews with Dr. Ian Zagon and Dr. Jill Smith, LDN researchers at Penn State) Print version to show your doctor. May 21th By Ali Gorman, RN -ABC News affiliate in Hershey Pennsylvania and many more reports in the Media section... GO VICKI !!! Oct. 21st 2009: Vicki will be back on the Sacramento Capitol steps. A promising MS drug has her walkin' - Vicki Finlayson says LDN has her walking strongly again May 16 2008 Sacramento Bee, Front Page WE DID IT !!! The LDN for MS Research Fund raised $25,000 in 2006 It has been given to the Univ. CA San Francisco MS Research Center. A crossover study to evaluated the effect of LDN on MS has been completed on 80 patients with MS, to be published Spring '08. Show your Dr this study! Press Release: Patient Advocates With Multiple Sclerosis Fund Clinical Trial of Promising Drug Many Say Has Helped; University of California, San Francisco MS Center to Conduct Study of Low-Dose Naltrexone Thank you to individual contributors and those who put on fundraising events! Benefit the LDN research Fundand Accelerated Cure Project for Multiple Sclerosis hosted by Vicki Finlayson LDN Fundraiser: Former firefighter Bill Roberts turned his life around in the past year with LDN. He has rallied his firefighter friends in the effort to get trials started to have the drug approved for treatment of Multiple Sclerosis.Read more... Fundraiser: Sierra Doherty is hiking the Colorado Trail to raise money for LDN research! Her mom has MS and uses LDN. Click here to donate to her effort -and get updates on Sierra's quest ! There are exciting developments in Low Dose Naltrexone (LDN) research. Visit the Research section for details on: Publication of the first medical hypothesis on LDN therapy for MS Status of clinical trials for LDN Annual LDN Conferences First Annual LDN Conference June 11th 2005 in NYC SammyJo's Presentation (PDF) | Conference Snapshots Post conference summary | Dr Larry Frieders summary |Attendee commentary Patient Initiated Research / Evidence-based Medicine Four key questions answered by 267 LDN users in Survey 1: Very low relapse rate of 0.2, or 1 in 5 years 70% report symptom improvement 45% think progression has stopped 76% say LDN is working for them, will continue therapy I started this site in the Spring of 2004 to confirm that others were seeing the same positive results I was. Thank you to the hundreds of LDNers contributing their experiences. I hope scientific research will accelerate and determine why so many of us are experiencing positive results. Change in EDSS disability score before after LDN is measured by Survey 2. Follow the Surveys link for result details. The surveys are comprised of a representative sampling of all types of MS (RRMS, SPMS, PPMS). This is important information from patients on the frontlines, and must be followed up by clinical researchers. Naltrexone is an FDA-approved drug. LDN is an off-label use of naltrexone in a low dosage. It does requires a prescription from a doctor. See Resources for help finding a prescriber or pharmacy, and info on LDN for other autoimmune disorders, cancer or HIV. Never doubt that a small group of thoughtful committed citizens can change the world; indeed, it’s the only thing that ever has. - Margaret Mead

TAGS:Dose Low Therapy 

<<< Thank you for your visit >>>

Hot Websites